S&P 500   3,328.09 (+0.01%)
DOW   27,233.95 (+0.12%)
QQQ   271.69 (+0.24%)
AAPL   446.60 (+1.44%)
MSFT   213.02 (+0.04%)
FB   261.79 (+5.09%)
GOOGL   1,491.22 (+0.82%)
AMZN   3,194.20 (-0.34%)
NVDA   449.88 (-0.35%)
CGC   18.22 (-5.15%)
BABA   261.04 (-1.46%)
TSLA   1,491.09 (+0.41%)
MU   48.80 (-4.41%)
GE   6.34 (-0.94%)
AMD   85.98 (+0.79%)
T   29.80 (-0.17%)
F   6.94 (-0.29%)
ACB   10.26 (-4.20%)
GILD   68.80 (-0.29%)
NFLX   502.96 (+0.17%)
DIS   129.02 (+1.10%)
BAC   25.44 (+0.20%)
BA   173.38 (-0.52%)
S&P 500   3,328.09 (+0.01%)
DOW   27,233.95 (+0.12%)
QQQ   271.69 (+0.24%)
AAPL   446.60 (+1.44%)
MSFT   213.02 (+0.04%)
FB   261.79 (+5.09%)
GOOGL   1,491.22 (+0.82%)
AMZN   3,194.20 (-0.34%)
NVDA   449.88 (-0.35%)
CGC   18.22 (-5.15%)
BABA   261.04 (-1.46%)
TSLA   1,491.09 (+0.41%)
MU   48.80 (-4.41%)
GE   6.34 (-0.94%)
AMD   85.98 (+0.79%)
T   29.80 (-0.17%)
F   6.94 (-0.29%)
ACB   10.26 (-4.20%)
GILD   68.80 (-0.29%)
NFLX   502.96 (+0.17%)
DIS   129.02 (+1.10%)
BAC   25.44 (+0.20%)
BA   173.38 (-0.52%)
S&P 500   3,328.09 (+0.01%)
DOW   27,233.95 (+0.12%)
QQQ   271.69 (+0.24%)
AAPL   446.60 (+1.44%)
MSFT   213.02 (+0.04%)
FB   261.79 (+5.09%)
GOOGL   1,491.22 (+0.82%)
AMZN   3,194.20 (-0.34%)
NVDA   449.88 (-0.35%)
CGC   18.22 (-5.15%)
BABA   261.04 (-1.46%)
TSLA   1,491.09 (+0.41%)
MU   48.80 (-4.41%)
GE   6.34 (-0.94%)
AMD   85.98 (+0.79%)
T   29.80 (-0.17%)
F   6.94 (-0.29%)
ACB   10.26 (-4.20%)
GILD   68.80 (-0.29%)
NFLX   502.96 (+0.17%)
DIS   129.02 (+1.10%)
BAC   25.44 (+0.20%)
BA   173.38 (-0.52%)
S&P 500   3,328.09 (+0.01%)
DOW   27,233.95 (+0.12%)
QQQ   271.69 (+0.24%)
AAPL   446.60 (+1.44%)
MSFT   213.02 (+0.04%)
FB   261.79 (+5.09%)
GOOGL   1,491.22 (+0.82%)
AMZN   3,194.20 (-0.34%)
NVDA   449.88 (-0.35%)
CGC   18.22 (-5.15%)
BABA   261.04 (-1.46%)
TSLA   1,491.09 (+0.41%)
MU   48.80 (-4.41%)
GE   6.34 (-0.94%)
AMD   85.98 (+0.79%)
T   29.80 (-0.17%)
F   6.94 (-0.29%)
ACB   10.26 (-4.20%)
GILD   68.80 (-0.29%)
NFLX   502.96 (+0.17%)
DIS   129.02 (+1.10%)
BAC   25.44 (+0.20%)
BA   173.38 (-0.52%)
Log in

NYSEAMERICAN:DXRDaxor Stock Price, Forecast & News

$17.80
+0.15 (+0.85 %)
(As of 08/6/2020 12:22 PM ET)
Add
Compare
Today's Range
$17.50
Now: $17.80
$17.80
50-Day Range N/A
52-Week Range
$7.85
Now: $17.80
$24.08
Volume2,691 shs
Average Volume17,322 shs
Market Capitalization$69.23 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.72 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:DXR
CUSIPN/A
Phone+1-212-3308500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$69.23 million
Next Earnings DateN/A
OptionableNot Optionable
$17.80
+0.15 (+0.85 %)
(As of 08/6/2020 12:22 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DXR News and Ratings via Email

Sign-up to receive the latest news and ratings for DXR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Daxor (NYSEAMERICAN:DXR) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Daxor?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Daxor in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Daxor
.

What price target have analysts set for DXR?

1 equities research analysts have issued twelve-month price targets for Daxor's stock. Their forecasts range from $18.00 to $18.00. On average, they expect Daxor's share price to reach $18.00 in the next year. This suggests a possible upside of 1.1% from the stock's current price.
View analysts' price targets for Daxor
.

Has Daxor been receiving favorable news coverage?

Media coverage about DXR stock has trended very negative recently, according to InfoTrie. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Daxor earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future.
View the latest news about Daxor
.

Are investors shorting Daxor?

Daxor saw a decrease in short interest in July. As of July 31st, there was short interest totaling 22,600 shares, a decrease of 10.7% from the July 15th total of 25,300 shares. Based on an average daily volume of 11,300 shares, the days-to-cover ratio is currently 2.0 days. Approximately 2.4% of the company's shares are short sold.
View Daxor's Current Options Chain
.

Who are some of Daxor's key competitors?

What other stocks do shareholders of Daxor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Daxor investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Pfizer (PFE), ContraFect (CFRX), Dynavax Technologies (DVAX), Micron Technology (MU), Sanofi (SNY), Verastem (VSTM) and Cidara Therapeutics (CDTX).

Who are Daxor's key executives?

Daxor's management team includes the following people:
  • Mr. Michael Richard Feldschuh, Chairman, Pres & CEO (Age 50)
  • Mr. Jonathan Adam Feldschuh, Chief Scientific Officer & Director (Age 54)
  • Mr. Robert J. Michel CPA, Chief Financial Officer (Age 62)
  • Ms. Kathryn A. Kornafel, VP of Marketing & Commercial Devel.
  • Mr. Guido Manzo, VP of Sales

What is Daxor's stock symbol?

Daxor trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "DXR."

How do I buy shares of Daxor?

Shares of DXR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Daxor's stock price today?

One share of DXR stock can currently be purchased for approximately $17.80.

How big of a company is Daxor?

Daxor has a market capitalization of $69.23 million.

What is Daxor's official website?

The official website for Daxor is www.daxor.com.

How can I contact Daxor?

Daxor's mailing address is 350 5th Ave Ste 4740, NEW YORK, NY 10118-0002, United States. The company can be reached via phone at +1-212-3308500.

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.